Magnetic resonance-guided radiotherapy for advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of radiation therapy that uses real-time MRI imaging to adjust the radiation precisely to your tumor. It is designed to improve the accuracy of treatment for locally advanced rectal cancer, potentially reducing damage to nearby healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have stage II or III rectal cancer that has not spread to distant organs, confirmed by MRI or ultrasound.
- The lower edge of the tumor must be within 10 cm (about 4 inches) from the anal verge.
- Your cancer must be a type called rectal adenocarcinoma, confirmed by biopsy.
- You must be in generally good health, able to perform daily activities, and have adequate organ function (blood counts, liver and kidney function within limits).
- You have not had prior radiation therapy to the same area, and you have not had prior surgery for this cancer (except a temporary colostomy), chemotherapy, or other anti-cancer treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining chemotherapy with high-dose radiation guided by MRI (a special scan) can better treat low rectal cancer. It may help shrink the tumor and improve local control while targeting the tumor more precisely.
This trial tests a new way to give high-dose radiation to rectal cancer tumors while avoiding the bladder and bowels. The goal is to cure the cancer without removing the rectum, so you may keep normal bowel function.
This trial studies a total “before-surgery” treatment plan for locally advanced rectal cancer, using MRI (a detailed scan) to help guide radiation. It may help patients by aiming to shrink the tumor and improve the chance of successful surgery.
This trial tests a new combination of short-course radiation, a targeted drug (fruquintinib), and an immunotherapy drug (PD-1 inhibitor) to treat rectal cancer before surgery. It aims to shrink the tumor and improve outcomes for patients with a specific type of rectal cancer.
This study tests a new MRI-guided approach to treat rectal cancer without removing the rectum, aiming to preserve quality of life. It may be an option for patients with stage II or III rectal cancer who are healthy enough for intensive treatment.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.